Información de Supernus Pharmaceuticals Inc, dividendo de Supernus Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Supernus Pharmaceuticals Inc Compañía

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.

Información de Supernus Pharmaceuticals Inc



Símbolo de cotizaciónSUPN

Nombre de la empresaSupernus Pharmaceuticals Inc

Fecha de salida a bolsaDec 28, 2010

Director ejecutivoKhattar (Jack A)

Número de empleados674

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 28

Dirección9715 Key West Avenue

CiudadROCKVILLE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal20850

Teléfono13018382500

Sitio Webhttps://www.supernus.com

Símbolo de cotizaciónSUPN

Fecha de salida a bolsaDec 28, 2010

Director ejecutivoKhattar (Jack A)

Ejecutivos de Supernus Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.25M

+1.54%

Mr. Frederick M. Hudson, CPA

Independent Director

60.41K

-8.89%

Dr. Georges Gemayel, Ph.D.

Independent Director

27.28K

-39.89%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

27.05K

+16.55%

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

17.87K

+1.87%

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

16.31K

--

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

12.73K

+16.16%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

7.50K

+41.59%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Mr. Peter Vozzo

Investor Relations

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.25M

+1.54%

Mr. Frederick M. Hudson, CPA

Independent Director

60.41K

-8.89%

Dr. Georges Gemayel, Ph.D.

Independent Director

27.28K

-39.89%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

27.05K

+16.55%

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

17.87K

+1.87%

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

16.31K

--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Net product sales-Qelbree

81.42M

42.38%

Net product sales - GOCOVRI

40.85M

21.26%

Collaboration revenue

20.16M

10.50%

Net product sales- Oxtellar XR

12.02M

6.25%

Net product sales-APOKYN

10.39M

5.41%

Otro

27.27M

14.20%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

192.10M

100.00%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Net product sales-Qelbree

81.42M

42.38%

Net product sales - GOCOVRI

40.85M

21.26%

Collaboration revenue

20.16M

10.50%

Net product sales- Oxtellar XR

12.02M

6.25%

Net product sales-APOKYN

10.39M

5.41%

Otro

27.27M

14.20%

Estadísticas de accionistas

Actualizado: sáb., 21 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.58%

The Vanguard Group, Inc.

10.48%

Millennium Management LLC

5.70%

Armistice Capital LLC

4.80%

Dimensional Fund Advisors, L.P.

4.71%

Otro

60.73%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

13.58%

The Vanguard Group, Inc.

10.48%

Millennium Management LLC

5.70%

Armistice Capital LLC

4.80%

Dimensional Fund Advisors, L.P.

4.71%

Otro

60.73%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

47.62%

Investment Advisor/Hedge Fund

27.76%

Hedge Fund

21.81%

Individual Investor

4.41%

Research Firm

2.30%

Pension Fund

1.58%

Venture Capital

1.41%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.21%

Participación institucional



Actualizado: lun., 5 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

613

59.41M

103.62%

-4.43M

2025Q3

575

60.19M

104.97%

-3.36M

2025Q2

565

63.61M

113.46%

-2.51M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

2023Q3

534

60.88M

111.42%

-4.46M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

7.64M

13.33%

-369.50K

-4.61%

Sep 30, 2025

The Vanguard Group, Inc.

6.03M

10.52%

-161.86K

-2.61%

Sep 30, 2025

Armistice Capital LLC

2.84M

4.95%

-1.98M

-41.06%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

3.00M

5.24%

-19.27K

-0.64%

Sep 30, 2025

Nomura Investment Management Business Trust

2.53M

4.42%

-230.59K

-8.35%

Sep 30, 2025

Point72 Asset Management, L.P.

1.76M

3.07%

+1.25M

+246.89%

Sep 30, 2025

Khattar (Jack A)

2.21M

3.86%

+59.32K

+2.76%

Oct 09, 2025

State Street Investment Management (US)

2.19M

3.82%

-21.00K

-0.95%

Sep 30, 2025

Renaissance Technologies LLC

1.74M

3.04%

+85.30K

+5.15%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

AdvisorShares Psychedelics ETF

7.48%

iShares Neuroscience and Healthcare ETF

3.83%

Invesco Pharmaceuticals ETF

3.32%

State Street SPDR S&P Pharmaceuticals ETF

3.11%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.21%

Invesco S&P SmallCap Health Care ETF

1.89%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.63%

Lattice Hartford Multifactor Small Cap ETF

1.3%

iShares U.S. Pharmaceuticals ETF

1.14%

First Trust Multi-Manager Small Cap Opportunities ETF

0.68%

AdvisorShares Psychedelics ETF

Proporción7.48%

iShares Neuroscience and Healthcare ETF

Proporción3.83%

Invesco Pharmaceuticals ETF

Proporción3.32%

State Street SPDR S&P Pharmaceuticals ETF

Proporción3.11%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción2.21%

Invesco S&P SmallCap Health Care ETF

Proporción1.89%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.63%

Lattice Hartford Multifactor Small Cap ETF

Proporción1.3%

iShares U.S. Pharmaceuticals ETF

Proporción1.14%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción0.68%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos